<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128579</url>
  </required_header>
  <id_info>
    <org_study_id>EQ001-19-002</org_study_id>
    <nct_id>NCT04128579</nct_id>
  </id_info>
  <brief_title>Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis</brief_title>
  <acronym>EQUALISE</acronym>
  <official_title>A Phase 1b Multiple Ascending-dose Study of EQ001 in Subjects With Systemic Lupus Erythematosus With or Without Active Proliferative Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Equillium</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocon Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Equillium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical&#xD;
      activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without&#xD;
      Active Proliferative Lupus Nephritis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll approximately 55 subjects, with up to 5 dose escalating cohorts of 6&#xD;
      open-label subjects enrolled for Type A-SLE and a single dose cohort of approximately 20&#xD;
      open-label subjects enrolled for Type B-Lupus Nephritis.&#xD;
&#xD;
      Subjects will receive itolizumab administered subcutaneously every two weeks for a total of&#xD;
      either 2 (Type A) or 13 (Type B) doses with 4 or 12 weeks of follow-up after the last dose of&#xD;
      investigational product.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>cohort based escalation of 6 subjects (Type A) single dose cohort of 20 subjects (Type B)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Type A and Type B are open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>Type A up to Day 57 or Type B up to Day 253</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the PK of itolizumab</measure>
    <time_frame>Type A up to Day 57 or Type B up to Day 253</time_frame>
    <description>To characterize the pharmacokinetics of itolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD6 receptor occupancy</measure>
    <time_frame>Type A up to Day 57 or Type B up to Day 253</time_frame>
    <description>the % levels of free versus EQ001-bound CD6 receptor on T cells</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Lupus Erythematosus</condition>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>EQ001 Type A cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EQ001 administered in an unblinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 2 doses (up to 5 cohorts with dosing to be determined in the range of 0.4 -- 3.2 mg/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EQ001 for Type B cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EQ001 administered in an unblinded single dose cohort by subcutaneous injection every two weeks for a total of 13 doses (1.6 mg/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itolizumab [Bmab 600]</intervention_name>
    <description>EQ001</description>
    <arm_group_label>EQ001 Type A cohort</arm_group_label>
    <arm_group_label>EQ001 for Type B cohort</arm_group_label>
    <other_name>Bmab600</other_name>
    <other_name>Itolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Type A Cohort Key Inclusion Criteria:&#xD;
&#xD;
          1. Is male or female, age ≥ 18 and ≤ 75 years&#xD;
&#xD;
          2. Has previously been documented to have met or currently meets Systemic Lupus&#xD;
             International Collaborating Clinics (SLICC) and/or American College of Rheumatology&#xD;
             (ACR) criteria for SLE&#xD;
&#xD;
          3. Received at least 1 immunosuppressive or immunomodulatory treatment for SLE at any&#xD;
             time in the past or currently&#xD;
&#xD;
          4. Has documented elevation of antinuclear antibodies (ANA) in the past or during&#xD;
             Screening&#xD;
&#xD;
          5. Restricted SLE treatments are stable and/or washed out&#xD;
&#xD;
          6. During Screening, has adequate hematologic function&#xD;
&#xD;
        Type B Cohort Key Inclusion Criteria:&#xD;
&#xD;
          1. Is male or female, age ≥ 18 and ≤ 75 years&#xD;
&#xD;
          2. Meets SLICC and/or ACR criteria for SLE&#xD;
&#xD;
          3. Kidney biopsy with a histologic diagnosis of LN Classes III or IV (+/- V)&#xD;
&#xD;
          4. Has a urine protein to creatinine ratio of &gt; 1000 mg/g&#xD;
&#xD;
          5. Requires induction treatment due to newly diagnosed LN or relapsing/flaring disease.&#xD;
&#xD;
          6. During Screening has adequate hematologic function&#xD;
&#xD;
          7. Restricted SLE treatments are stable and/or washed out&#xD;
&#xD;
          8. Most recent eGFR ≥ 40 mL/min/1.73m2&#xD;
&#xD;
          9. Has evidence of serologic activity during Screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Acute or chronic infections requiring systemic antibacterial, antifungal, or antiviral&#xD;
             therapy&#xD;
&#xD;
          2. Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV&#xD;
&#xD;
          3. Active TB or a positive TB test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Kalunian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Kim</last_name>
    <phone>858 412 5302</phone>
    <email>clinicaltrials@equilliumbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AKDHC Medical Research Services, LLC</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Perlman Ambulatory Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida - Clearwater</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765-2616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre for Rheumatology, Immunology and Arthritis</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site Partners Leesburg, LLC</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SouthCoast Research Center Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Trials</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omega Research Maitland, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgia Nephrology</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine, Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health / Division of Rheumatology</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center, Div of Nephrology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research Center, LLC</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prolato Clinical Research Center (PCRC)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Post Graduate Institute of Medical Education and Research (PGIMER)</name>
      <address>
        <city>Chandigarh</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medanta - The Medicity Hospital</name>
      <address>
        <city>Gurugramam</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MAX Super Specialty Hospital</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jawaharlal Nehru Institute of Postgraduate Medical Education and Research (JIPMER)</name>
      <address>
        <city>Puducherry</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miedzyleski Szpital Specjalistyczny w Warszawie, Oddzial Nefrologiczny i Stacja Dializ</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi, Klinika Nefrologii, Hipertensjologii</name>
      <address>
        <city>Łódź</city>
        <zip>92-213</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://equilliumbio.com/</url>
    <description>company website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Active Proliferative Lupus Nephritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

